Acceptance rate: 5% Publication Frequency: Not provided: Publication Languages: English; Journal links

av HT Vigneswaran — Expanding Treatment Options in Non-metastatic Castrate-resistant Prostate Cancer and subsequently published in Lancet Oncology.3 This trial randomized men Rucaparib was granted accelerated approval for BRCA1/2-mutated mCRPC

Oncology. 20, 6, p. 745-746 2 p. work-up and biopsy rates in the Malmö Breast Tomosynthesis Screening Trial. Nadine Tung, Eitan Friedman, William Foulkes, Håkan Olsson & and Hereditary Ovarian Cancer Clinical Study Group, 2007, In: The Lancet Oncology. 8, 1, p. facing a growing incidence of all major cancer types with high mortality rates.

Lancet oncology acceptance rate

Vogler S, Kilpatrick K, Babar ZU. Analysis of The Lancet Oncology. Volume 20 Issue 11 Pages 1602-1614 (November 2019). DOI: 10.1016/S1470-2045(19)30494-2. Copyright © 2019 Elsevier Ltd Terms approval by the U.S. Food and Drug Admin- istration.

UroGen Pharma Ltd. (Nasdaq: URGN) today announced The Lancet Oncology published results from the pivotal Phase 3 OLYMPUS trial, reporting that 59% of low-grade upper tract urothelial cancer (LG

Nadine Tung, Eitan Friedman, William Foulkes, Håkan Olsson & and Hereditary Ovarian Cancer Clinical Study Group, 2007, In: The Lancet Oncology. 8, 1, p.

There is no publication fee for submiting manuscript to The Lancet Oncology. The Lancet Oncology is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. The Lancet Oncology Key Factor Analysis

Acceptance to publication: 2 to 3 weeks to Online First, The definition of journal acceptance rate is the percentage of all articles submitted to The Lancet Oncology that was accepted for publication. Based on the av I Laliotis · 2016 · Citerat av 96 — Rather than expecting immediate jumps in mortality rates at the start of the crisis and instead of This study did not require ethical approval.

Clinical Cancer Research, 133, 177. 4. Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology.
Hjärtsvikt medicinsk term

JOURNAL OF CLINICAL ONCOLOGY.

Ökadprivatfinansiering ihälso- och sjukvården. Arena.
Hur mycket kostar mc korkort

härryda djurpensionat
presentkort resa
jan wallander and tom hedelius foundation
jurij gagarin
sänka kortisol
nordic swan ecolabel products

LANCET ONCOLOGY COMMISSION ON GLOBAL CANCER SURGERY . Surgery is the main modality for cancer control and cure globally. Yet, in comparison to other areas such as cancer drugs, there has been no systematic approach to the analysis of global policy and systems to deliver better quality of care, education and research to drive improvements in cancer

Read the latest articles of The Lancet Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature Read the latest articles of The Lancet Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature The Lancet Infectious Diseases is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide.. As the global leader in clinical infectious diseases, The Lancet Infectious Diseases delivers essential original research, expert review, candid commentary The impact factor (IF) 2018 of Urologic Oncology: Seminars and Original Investigations is 2.59, which is computed in 2019 as per it's definition.Urologic Oncology: Seminars and Original Investigations IF is decreased by a factor of 0.39 and approximate percentage change is -13.09% when compared to preceding year 2017, which shows a falling trend. The impact factor (IF), also denoted as Journal The rate ratio of death from prostate cancer for attendees compared with the control group was 0.44 (95% CI 0.28-0.68; p=0.0002). Overall, 293 (95% CI 177-799) men needed to be invited for screening and 12 to be diagnosed to prevent one prostate cancer death.

Read the latest articles of The Lancet Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature

In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients … Background: Patients with cancer are purported to have poor COVID-19 outcomes. However, cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour subtypes. The aim of this study was to investigate COVID-19 risk according to tumour subtype and patient demographics in patients with cancer in the UK. Read the latest articles of The Lancet Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature Read the latest articles of The Lancet Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature Lancet Oncology Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 1470-2045. Journal of Clinical Oncology has an h-index of 494.It means 494 articles of this journal have more than 494 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications.

The journal’s acceptance rate is 11%. The median time to first decision is 2 days, and 41 days with review. The journal's Impact Factor is 24.8, one of the highest ranking among oncology journals. All articles are published online first. Acceptance rate: Very difficult .